HALO:NSD-Halozyme Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 62.54

Change

-0.41 (-0.65)%

Market Cap

USD 7.28B

Volume

1.23M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.53 (-0.30%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.46 (-1.98%)

USD 76.39B
ARGX argenx NV ADR

-3.01 (-0.49%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-8.81 (-3.48%)

USD 31.94B
ONC BeiGene, Ltd.

-3.69 (-1.39%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.39 (+1.18%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.30 (-1.49%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-8.82 (-2.73%)

USD 14.37B
INCY Incyte Corporation

-2.01 (-3.24%)

USD 14.22B
MRNA Moderna Inc

-0.90 (-2.59%)

USD 13.74B

ETFs Containing HALO

FBT:LSE First Trust Global Funds .. 3.92 % 0.00 %

-13.30 (-0.53%)

USD 8.62M
FBTU:LSE First Trust Global Funds .. 3.92 % 0.00 %

-0.15 (-0.53%)

USD 8.52M
ROYL:AU BetaShares Global Royalti.. 3.80 % 0.00 %

+0.01 (+-0.53%)

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.12 % 0.00 %

-0.07 (-0.53%)

N/A
SCDS JPMorgan Fundamental Data.. 1.13 % 0.00 %

-0.33 (-0.53%)

USD 6.21M
AGED:SW iShares Ageing Population.. 0.57 % 0.00 %

+0.10 (+-0.53%)

N/A
ETLZ:XETRA L&G Russell 2000 US Small.. 0.54 % 0.00 %

-0.26 (-0.53%)

USD 0.09B
ITWO Proshares Russell 2000 Hi.. 0.28 % 0.00 %

-0.19 (-0.53%)

USD 0.05B
UWM ProShares Ultra Russell20.. 0.25 % 0.95 %

-0.54 (-0.53%)

USD 0.32B
HDG ProShares Hedge Replicati.. 0.04 % 0.95 %

-0.11 (-0.53%)

USD 0.02B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-3.59 (-0.53%)

N/A
GSC Goldman Sachs ETF Trust 0.00 % 1.25 %

-0.38 (-0.53%)

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.68 (-0.53%)

N/A
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

N/A

USD 0.03B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.01 (+-0.53%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+0.75 (+-0.53%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-4.65 (-0.53%)

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

-0.23 (-0.53%)

USD 0.22B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

-11.50 (-0.53%)

USD 0.22B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.12 (+-0.53%)

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.81% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.81% 90% A- 93% A
Trailing 12 Months  
Capital Gain 53.25% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.25% 88% B+ 90% A-
Trailing 5 Years  
Capital Gain 319.73% 93% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 319.73% 93% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 20.16% 66% D+ 74% C
Dividend Return 20.16% 66% D+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.76% 73% C 47% F
Risk Adjusted Return 49.45% 94% A 77% C+
Market Capitalization 7.28B 96% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.